Report overview
Targeted therapy is?a type of cancer treatment that uses drugs or other substances to precisely identify and attack certain types of cancer cells. A targeted therapy can be used by itself or in combination with other treatments, such as traditional or standard chemotherapy, surgery, or radiation therapy.
This report aims to provide a comprehensive presentation of the global market for Cancer Targeted Small Molecule Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Targeted Small Molecule Therapy. This report contains market size and forecasts of Cancer Targeted Small Molecule Therapy in global, including the following market information:
Global Cancer Targeted Small Molecule Therapy Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Cancer Targeted Small Molecule Therapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Sorafenib Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Cancer Targeted Small Molecule Therapy include Bayer, Eisai, Zelgen, Cipla, Natco Pharma, AstraZeneca, Novartis, Roche and Bristol-Myers Squibb, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cancer Targeted Small Molecule Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cancer Targeted Small Molecule Therapy Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Cancer Targeted Small Molecule Therapy Market Segment Percentages, by Type, 2022 (%)
Sorafenib
Lenvatinib
Regorafenib
Osimertinib
Anlotinib
Alectinib
Other
Global Cancer Targeted Small Molecule Therapy Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Cancer Targeted Small Molecule Therapy Market Segment Percentages, by Application, 2022 (%)
Hospital
Retail Pharmacy
Other
Global Cancer Targeted Small Molecule Therapy Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Cancer Targeted Small Molecule Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cancer Targeted Small Molecule Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Cancer Targeted Small Molecule Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
Eisai
Zelgen
Cipla
Natco Pharma
AstraZeneca
Novartis
Roche
Bristol-Myers Squibb
Pfizer
BEACON Pharma
Jiangxi Shanxiang
Yao Pharma
CSPC
CHIATAI Tianqing
Simcere
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cancer Targeted Small Molecule Therapy, market overview.
Chapter 2: Global Cancer Targeted Small Molecule Therapy market size in revenue.
Chapter 3: Detailed analysis of Cancer Targeted Small Molecule Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cancer Targeted Small Molecule Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
